Welcome to Last Week in Micro-Cap. This week, we have the full spectrum of equity destruction: a classic biotech bankruptcy, a failed Alzheimer's clinical trial, and a company that named itself "Parabolic" just days before Nasdaq showed it the door. But we have to start with the most impressive unforced error of the year: a company that sold equity for Bitcoin, left it on a random crypto exchange, and is now restating a year of financials because they can't get their money out.
Datavault AI Inc. (DVLT)
The Filing: Datavault determined that four quarters of financials (Q3 2025 through Q2 2026) can no longer be relied upon. Why? Because last year, they sold $150 million worth of equity to Scilex Holding Co. in exchange for Bitcoin. Datavault booked the crypto as a digital asset. The problem is they left the Bitcoin in a wallet at the exchange Biconomy, tried to withdraw it in June, and nothing happened. So now they have to reclassify the asset as a "subscription receivable" and write down up to $92.2 million in assets. They are reassessing their going concern status.
The Aftermath: "Not your keys, not your coins" is usually a retail problem, but it translates beautifully into GAAP accounting. Since the filing, DVLT shares crashed 50% to roughly six cents. The company is now floating a desperate 1-for-50 reverse split proposal ahead of its annual meeting. It takes a unique talent to merge AI buzzwords, biotech cross-holdings, and offshore crypto custody risk into a single catastrophic 8-K, but Datavault pulled it off.
BioXcel Therapeutics, Inc. (BTAI)
The Filing: BioXcel filed for Chapter 11 bankruptcy and sold substantially all of its neuroscience assets—including its flagship agitation drug IGALMI—to Teva Pharmaceuticals for $57.5 million upfront. They fired the entire C-suite and renamed the shell "BX Liquidation, Inc."
The Aftermath: This is the terminal stage of the biotech lifecycle. You build a clinically valid asset, run out of runway 11 weeks before a crucial FDA decision, and big pharma scoops it up for a fraction of its value in bankruptcy court. The stock plunged 45% and was delisted to the OTC Pink sheets. Retail investors are currently learning about the absolute ruthlessness of the bankruptcy waterfall: Teva gets a bargain, secured creditors take whatever cash is left, and the common equity gets completely wiped out.
Parabolic Technologies, Inc. (PARA, formerly BNZI)
The Filing: Parabolic (formerly Banzai International) received a Staff Delisting Determination from Nasdaq for failing the $1.00 bid price rule. Normally you get 180 days to fix this, but Parabolic has executed a cumulative 1-for-2,000 in reverse stock splits over the last two years, maxing out their limit and voiding the grace period.
The Aftermath: In August, Banzai International rebranded and changed its ticker to PARA. Naming your company "Parabolic" right before Nasdaq kicks you out for mechanically suppressing your share count is a breathtaking choice. They plan to appeal the delisting, but they also just filed an S-1 to try and raise another $11.8 million in a stock offering. Selling equity when your stock is actively being evicted from the exchange is an uphill battle.
Acumen Pharmaceuticals, Inc. (ABOS)
The Filing: Acumen announced that sabirnetug, its lead Alzheimer's candidate, failed to meet primary and secondary endpoints in its Phase 2 ALTITUDE-AD trial. They are terminating development and implementing cash conservation measures while looking for a buyer.
The Aftermath: The stock instantly evaporated, dropping 86% to $0.33. Analysts downgraded it en masse, shifting it from a clinical-stage biotech to a residual value play. Acumen technically has around $79 million in cash, and its market cap is now sitting around $25 million. But veteran micro-cap traders know that "cash conservation" is just corporate speak for burning cash slightly slower. Unless they liquidate immediately, that discount to cash will vanish as wind-down costs eat the treasury.
OSR Health, Inc. (OSRH)
The Filing: The Nasdaq Hearings Panel formally denied OSR Health's request for continued listing, officially booting them to the OTC market.
The Aftermath: The funniest part of this delisting is how hard the market tried to prevent it. Back in August, right before their compliance deadline, OSRH's 18.5 million share float was traded 20 times over in a single day as retail churned 370 million shares to push the price up. They hit $0.84, failed by 16 cents, and then the bottom fell out. The CEO tried to argue to the panel that this extraordinary market activity proved they deserved to stay. The panel disagreed. The stock is now languishing OTC.
What to Watch Next Week
Keep an eye on Datavault's proxy vote for that 1-for-50 reverse split. Will shareholders authorize a split for a company whose main asset is locked on an unresponsive crypto exchange? Also, watch the OTC tape for BTAI (BX Liquidation)—retail usually bids these bankrupt shells up one last time before the equity is officially canceled. See you next week.